Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human, proof-of-concept phase I study of PIN-2 in oncology patients with solid tumors.

Next Previous
Trial Profile

A first-in-human, proof-of-concept phase I study of PIN-2 in oncology patients with solid tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs PIN 2 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept

    • Most Recent Events

    • 22 Nov 2017 New trial record
    • 15 Nov 2017 According to a PIN Pharma Inc media release, the company today announced the initiation of this study and anticipate having interim data by the upcoming JP Morgan conference this January 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top